Universidad De Barcelona

Fundacio Institut D'investigacio En Ciencies De La Salut Germans Trias I Pujol

Maria Rosa Sarrias Fornés

Francisco Lozano Soto

Cristina Vilaplana Massaguer

Gemma Aran Canals

Lucía Sanjurjo Bouza

ÈRica TÉLLEZ Caballero

Francesc E BORRÁS Serres

The invention relates to a CD5L-binding agent or a pharmaceutical composition thereof for use in the treatment of cancer by inhibiting macrophage M2 activation or promoting lymphocyte activation.

Anti-CD5L antibody and uses thereof

The inventors have found that CD6, a member of the Scavenger Receptor Cysteine-Rich (SRSR) superfamily expressed on human lymphocytes binds to Gram-positive and Gram-negative bacteria, as well as to other microbial structures. Thus, a CD6 product is useful for the manufacture of a medicament for therapeutic and/or preventive treatment of an infectious disease or of an inflammatory condition related to an infectious disease or to the presence of a product derived from an infectious agent in a mammal including a human. Examples of such inflammatory conditions are systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis and septic shock.

Protein product for treatment of infectious diseases and related inflammatory processes

Growing community of inventors

Barcelona, Spain

Maria Rosa Sarrias Fornés